Pinnacle Associates’s Abivax ABVX Stock Holding History

Pinnacle Associates’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,864	Closed	-$248K	–	959
2026 Q2	$248K	Hold	1,864	–	–	﹤0.01%	864
2026 Q1	$208K	Buy	+1,864	New	+$221K	﹤0.01%	903

Other funds holding ABVX

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Syquant Capital SAS Paris, France $453M AUM 6.35% 1-Year Est. Return

Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return

Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Colonial River Investments Midlothian, Virginia $387M AUM 30.41% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Sax Wealth Advisors Parsippany, New Jersey $3.5B AUM 13.72% 1-Year Est. Return

Pinnacle Associates's ABVX Position: Q3 2026 in Review

Pinnacle Associates sold out of Abivax (ABVX) in Q3 2026, closing a stake of 1,864 shares — an estimated $248K sold.

Pinnacle Associates first reported a position in ABVX in Q1 2026 and held it in 2 quarters. The position peaked at $248K in Q2 2026. 41 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

Pinnacle Associates reported no remaining Abivax position as of Q3 2026 after selling out during the quarter.
Pinnacle Associates sold 1,864 Abivax shares in Q3 2026, an estimated $248K.
Pinnacle Associates first reported a position in Abivax in Q1 2026 and held it in 2 quarters.
Pinnacle Associates's Abivax position peaked at $248K in Q2 2026.
41 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.